Get the Stockscreener App
101.80
2.53%
2.51
Illumina Inc stock is traded at $101.80, with a volume of 1.96M.
It is up +2.53% in the last 24 hours and down -0.23% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$99.29
Open:
$100.05
24h Volume:
1.96M
Relative Volume:
0.92
Market Cap:
$15.65B
Revenue:
$4.28B
Net Income/Loss:
$1.26B
P/E Ratio:
12.89
EPS:
7.9
Net Cash Flow:
$943.00M
1W Performance:
+1.69%
1M Performance:
-0.23%
6M Performance:
+8.07%
1Y Performance:
-21.29%
1-Day Range:
$99.42
$103.65
1-Week Range:
$99.08
$103.65
52-Week Range:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
101.80 | 15.91B | 4.28B | 1.26B | 943.00M | 7.90 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Another FCA Cybersecurity Settlements Highlight DOJ’s Enforcement Priorities - JD Supra
New Empirical Research Report on Human Microbiome Sequencing - openPR.com
Immune Repertoire Sequencing Market Outlook (2025-2032): - openPR.com
Illumina names Nilesh Shah as head of region, AMEA - Medical Buyer
Risk adjusted return profile for Illumina Inc. analyzedEarnings Overview Report & AI Forecasted Entry and Exit Points - Newser
Ranking Illumina Inc. among high performing stocks via toolsJuly 2025 Volume & Technical Entry and Exit Tips - Newser
Nilesh Shah joins Illumina as Head of Region, AMEA - BioSpectrum Asia
Using R and stats models for Illumina Inc. forecasting2025 Technical Overview & Growth Focused Stock Reports - Newser
Chart based exit strategy for Illumina Inc.Fed Meeting & Growth Focused Stock Pick Reports - Newser
Will Illumina Inc. stock recover after recent dropChart Signals & High Accuracy Swing Trade Signals - Newser
Real time breakdown of Illumina Inc. stock performanceJobs Report & Momentum Based Trading Signals - Newser
Volatility clustering patterns for Illumina Inc.Bond Market & AI Forecasted Entry and Exit Points - Newser
Applying Elliott Wave Theory to Illumina Inc.Earnings Risk Report & Free Real-Time Volume Trigger Notifications - Newser
Icahn exits Illumina, Dana; boosts stakes in CVR Energy - MSN
How to monitor Illumina Inc. with trend dashboardsShare Buyback & High Accuracy Trade Alerts - Newser
What to expect from Illumina Inc. in the next 30 daysTrade Entry Report & Free Low Drawdown Momentum Trade Ideas - Newser
Illumina sets an example in disability inclusion - Illumina
Is Illumina Inc. stock heavily shortedWeekly Investment Summary & Verified Chart Pattern Signals - classian.co.kr
How to manage a losing position in Illumina Inc.July 2025 EndofMonth & Daily Profit Focused Screening - Newser
How to forecast Illumina Inc. trends using time seriesTrade Analysis Report & Fast Momentum Entry Tips - Newser
Best data tools to analyze Illumina Inc. stockQuarterly Trade Report & Growth Focused Entry Reports - Newser
Statistical indicators supporting Illumina Inc.’s strengthMarket Performance Report & Daily Risk Controlled Trade Plans - Newser
Price action breakdown for Illumina Inc.Swing Trade & AI Based Buy/Sell Signal Reports - Newser
The future of precision oncology: Scaling NGS with smarter variant interpretation - Illumina
What candlestick patterns are forming on Illumina Inc.2025 Market Outlook & Community Verified Trade Alerts - Newser
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina - ADVFN Brasil
Is Illumina Inc. on track to beat earningsJuly 2025 Summary & High Accuracy Swing Entry Alerts - newsyoung.net
Carl Icahn raises shared share stake in Centuri Holdings, dissolves in Dana, Illumina - MarketScreener
Carl Icahn Exits Dana, Illumina, Increases CVR Energy Stake in Q2 - AInvest
Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know - Yahoo Finance
Now that NGS is more affordable, how can we make it easier? - Illumina
Illumina shares rise 1.18% premarket after Daiwa Securities downgrades to Neutral from Outperform. - AInvest
Illumina’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Illumina (NASDAQ:ILMN) Downgraded by Daiwa Capital Markets to Neutral - Defense World
Illumina Settles $9.8M False Claims Case Over Vulnerable Genomic Systems - WebProNews
[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know - TradingView
Illumina Downgraded to Neutral by Daiwa Securities - AInvest
Illumina Sees Future Rebound in China Sales - San Diego Business Journal
Daiwa Securities Downgrades Illumina to Neutral From Outperform, Adjusts Price Target to $94 From $124 - MarketScreener
US Personalized Medicine Market Trends and Company Analysis - GlobeNewswire
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche - Yahoo Finance
How Illumina Inc. stock performs during market volatilityMaximum Yield Stock Screener - classian.co.kr
Standard BioTools Announces SomaLogic Sale to Illumina - TipRanks
Latest Cybersecurity False Claims Act Settlement with Diagnostics Provider Focuses on Sensitive Health Systems - Inside Privacy
Illumina price leans on SMA supportForecast today11-08-2025 - Economies.com
DNA Microarray Market to Grow at 9% CAGR, Driven by Personalized - openPR.com
Single Cell Genome Sequencing Market is evolving rapidly Through 2025 To 2032 | Illumina, Inc., Fludigim Corporation - openPR.com
What MACD and RSI say about Illumina Inc.Daily Swing Candidate Analysis with Chart Patterns - Newser
Is Illumina Inc. a strong growth stockEarnings Surprise Driven Picks - thegnnews.com
What makes Illumina Inc. stock price move sharplyMulti-Sector Diversified Watchlist - thegnnews.com
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Illumina Inc Stock (ILMN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thaysen Jacob | Chief Executive Officer |
May 12 '25 |
Buy |
80.88 |
6,500 |
525,732 |
77,540 |
| Thaysen Jacob | Chief Executive Officer |
May 13 '25 |
Buy |
80.84 |
5,850 |
472,942 |
83,390 |
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):